

In the Claims:

Amend claims 1 and 27 as follows:

*Sub C 4*  
~~1 (Amended) A recombinant conjugate antibody molecule, consisting of a bivalent monoclonal antibody moiety having heavy and light chains and specific for a surface structure of antigen presenting cells, genetically modified to contain at least one antigen moiety exclusively at at least one preselected site on said monoclonal antibody moiety, whereby said conjugate antibody molecule is capable of delivering said antigen moiety to the antigen presenting cells of a host and capable of eliciting an immune response to said antigen moiety in the host.~~

*Sub C 5*  
~~27. (Amended) An immunogenic composition, comprising, as an active component thereof, a conjugate antibody molecule consisting of [comprising] a bivalent monoclonal antibody moiety having heavy and light chains and specific for a surface structure of antigen presenting cells genetically modified to contain at least one antigen moiety exclusively at at least one preselected site on said monoclonal antibody moiety exclusively at at least one preselected site on said monoclonal antibody moiety, whereby said conjugate antibody molecule is capable of delivering said antigen moiety to the antigen presenting cells of a host and capable of eliciting an immune response to said antigen moiety in the host.~~

Cancel claims 26 and 29 to 33.

In the Drawings:

It is proposed to Amend Figures 1, 2, 3 and 4 as shown on the enclosed print in red.

REMARKS

In an Advisory Action on the parent application, the Examiner indicated that the Amendment submitted September 24, 1997 would not be entered in the parent filing, on the basis that:

"The proposed amendments to the claims would require an additional art search and application of any art that is found".